| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3801272 | Medicina Clínica | 2009 | 4 Pages |
Abstract
Omalizumab showed a marked global efficacy in more than 3 out of 4 patients suffering severe allergic asthma as revealed by physician overall assessment. Moreover significant improvements were observed in ACQ; AQLQ; AQLQ-symptoms at 2, 3 and 4 months of treatment, without significant changes in FEV1 probably due to chronic irreversible changes in airways.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Adalberto Pacheco-Galván, Miguel Hinojosa-MacÃas, Beatriz Hurtado-Barbudo, Jesús González-Cervera, Antonio Sueiro-Bendito,